March 2012 Issue of MMM
March 2012 issue
Editor's Desk
Features
MM&M Awards 2012: How to Win an Award
James Chase asked 16 of last year's judges about how entrants can improve their chances of winning an MM&M Award
State of Market Research: Analyze This
Market research must transform itself or run the risk of becoming obsolete. Marc Iskowitz teams with the PMRG and TGaS Advisors to review the cold ...
Specialty Pharma: Niches to Riches
Specialty biopharma firms are using razor-sharp therapeutic focus to target "niche buster" categories.
Co-pay Cards: House of Cards
Co-pay cards have proliferated, undermining payer benefit plans. Now, insurers are striking back against the cards.
MAHF Inductees 2012: Heroes' Welcome
It was a night to remember as the stars of medical advertising came out to welcome three more legends into the Hall of Fame
Vantage Point
Vantage Point: How social media can make an impact
Social media can have a far-reaching impact on study time, costs, quality and outcomes
Antidote
Antidote: The problems facing Avastin
Counterfeiters are making a version of Avastin that lacks the drug's main active ingredient
In Focus
Komen Foundation nurses damaged brand
Why the Susan G. Komen for the Cure Foundation's previously unassailable brand in healthcare fundraising may have sustained some permanent damage.
Professional Marketing
AstraZeneca to cut 7,300 more jobs
AstraZeneca confirmed rumors of another round of deep cuts, announcing that it will eliminate 7,300 positions.
Solicitor General sides with reps in GSK overtime case
The U.S. Solicitor General has filed an amicus brief taking the side of two pharmaceutical sales reps in the overtime case that they filed against ...
Professional Marketing briefs—March 2012
News on D&R Communications, Publicis Touchpoint Solutions, Santarus and Physicians Interactive
Med Ed Report
Allergan scrubs some patient data
Allergan removed some doctor-payment records from its website that the drugmaker had posted from 2010-2011 as a result of a Botox legal settlement.
Study says docs favor COI disclosure
About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest to patients.
Success seen in fighting CME bias
Progress in keeping commercial bias from industry-based certified CME is at hand, say those who produce and fund it.
Med Ed Report briefs—March 2012
News on FDA, Med-IQ, the American Medical Student Association, Best Practices, the American College of Physicians and CECity
Professional Media
Academics blast publishers' methods
An online protest has pulled the scientific publishing industry, and particularly Dutch publisher Elsevier, into a tug of war with writers.
Media Choice—March 2012
Glenn Kolansky, Board Certified Dermatologist, Adv. Dermatology Surgery & Laser Center, Red Bank, NJ.
Checking 'sanity,' but not accuracy
Open-access research project F1000 has launched a program in which submissions are published following an "initial sanity check" from the project's director of new product ...
Professional Media briefs—March 2012
News about Jobson Medical Information Holdings, Medical Prescribing Reference, DTW Research Marketing Group and Communications Media Inc./Compas
Partner Forum
Do reviews have an evidence gap?
Missing documents allegedly kept a review of Tamiflu from conclusively examining the drug's efficacy. Are reviews marred by publication and reporting biases? What can be ...
Digital Media
Coalition's gameplan for digital regs
Weary of FDA foot-dragging on digital and social media guidance for pharmas, a group of industry digerati put together guidelines of their own.
P&G plans to cut its ad costs by shifting to digital media
P&G has historically spent 9%-11% on advertising, but the company is looking for corners to cut and finding them in social media.
Digital media briefs—March 2012
News about AstraZeneca, Everyday Health and the AMA
Consumer Marketing
FDA study finds little harm in 'distracting visuals'
An FDA study on the power of background visuals found no evidence that consumer understanding of risk info is affected by the "emotional (affective) tone ...
DDR on DTC: Toviaz vs. Vesicare
Two brands are fighting for attention from OAB sufferers: GSK-Astellas's Vesicare and Pfizer's Toviaz. Their DTC approaches couldn't be more different.
J&J names new OTC group chair
J&J named Roberto Marques to serve as the company group chairman responsible for the recall-plagued McNeil Consumer Healthcare unit
Marketing Research
Market research kept out of Sunshine law
The Physician Payment Sunshine Act maintains the exclusion for marketing research incentives
German firm accused of data breach
Market research firm Pharmafakt GFD is accused of selling prescription info without removing data that can be used to trace identities.
Agency Business
Merck respiratory goes to McCann
McCann HumanCare landed the agency of record assignment for consumer advertising and communications on Merck's respiratory franchise
Dixon to lead MSL Group's measurement and analytics
MSLGroup Americas named Unilever's Janelle Dixon SVP director of insights creation and measurement.
Agency business briefs—March 2012
News about Ogilvy CommonHealth Worldwide, Draftfcb, D&R Communications, Moroney & Gill
Beltway Insider
As I See It: Global systems for quality and safety
It's time for a regulatory Marshall plan to help build global systems for quality and safety
Sens. Klobuchar, Collins push drug-shortage bill
U.S. senators Amy Klobuchar and Susan Collins are trying to quickly pass a bill addressing the growing drug shortage problem
User-fee inaction could cause logjam
Congressional inaction could lead to a huge new products-review backlog, according to FDA Matters editor Steven Grossman.
Viewpoint
The very public risks of celebrity endorsements
What happens when a celebrity goes off message, gets a DUI or is photographed eating a hamburger?
Private View
Private View: Breaking the Healthcare Barriers
Consumer work that creatively breaks the healthcare barriers and, most importantly, drives customers to act
At Work With
At Work With: Marsha Braverman
Marsha Braverman, Exec. Dir. of Marketing & Communications, Drexel Univ. College of Medicine
People
People Moves: March 2012
Manufacurer and agency hires and promotions
Name That Brand
Name That Brand—March 2012
This first-to-market drug's campaign asks consumers why they want to increase their chances of being cured.
Back Talk
CES: Convergence continues
The desire to reduce the cost of delivering care has led to redefining 'point of care'
MM&M Articles
- Five things for pharma marketers to know: Monday, May 22, 2017
- The FDA cites risk info in letter over Contrave DTC ad
- Five things for pharma marketers to know: Tuesday, May 23, 2017
- Five things for pharma marketers to know: Wednesday, May 24, 2017
- Following Tymlos approval, Radius uses Facebook to educate about osteoporosis
- Five things for pharma marketers to know: Friday, May 26, 2017
- Following Tymlos approval, Radius uses Facebook to educate about osteoporosis
- Five things for pharma marketers to know: Thursday, May 25, 2017
- Twitter launches DM cards for brands
- Five things for pharma marketers to know: Wednesday, May 24, 2017
Live at MM&M Transforming Healthcare
Pharma faces its 'oh, shit' moment
In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.
Merck, Takeda execs: Is AI the new bad app?
One executive referred to AI as a "black box" and as the "Tower of Babel."
Value-based care requires innovators to challenge the status quo
Execs stressed the importance of collaboration, consumer-mindedness.
Admetsys wins the 2017 MM&M Startup Showdown
The artificial pancreas can provide value to the health system.
Top 40 Healthcare Transformers
MM&M honors 40 upstarts and veteran innovation gurus.
Top 10 Innovation Catalysts
For the first time MM&M honors a group of 10 agency execs.
